Lupus (SLE): vizsgálatok itt: Argentína
15 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- Quilmes, San Miguel
- Életkor
- 5 év to 80 év
- People
- 1072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - 3. fázisTaking peoplePhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Where
- CABA, La Plata, Quilmes, San Miguel, San Miguel de Tucumán
- Életkor
- 12 év to 100 év
- People
- 550 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00 - 3. fázisTaking peopleA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Where
- Buenos Aires, CABA, Ciudad de Buenos Aires, La Plata, Quilmes, Rosario, San Fernando, San Miguel de Tucumán
- Életkor
- 18 év to 75 év
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Where
- C.a.b.a, Capital Federal, Córdoba, Mendoza, Quilmes, San Juan, San Miguel de Tucumán
- Életkor
- 16 év and over
- People
- 450 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00 - No phaseTaking peopleA Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Where
- Buenos Aires, Mendoza, Quilmes, San Miguel de Tucumán
- Életkor
- 16 év and over
- People
- 223 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07175285 - 2. fázisTaking peopleA Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- Where
- CABA, Capital Federal, General Paz, Maipu, Quilmes, San Miguel de Tucumán
- Életkor
- 18 év to 74 év
- People
- 405 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07409181 · EU 2025-523488-39-00 - 2. fázisTaking peopleA Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
- Where
- Buenos Aires, CABA
- Életkor
- 18 év and over
- People
- 30 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07598396 · EU 2024-519930-22-00 - 3. fázisCsak meghívásosA Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
- Where
- Buenos Aires, Mendoza, Quilmes, San Juan, San Miguel de Tucumán
- Életkor
- 16 év and over
- People
- 760 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00 - 3. fázisCsak meghívásosA Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
- Where
- Buenos Aires, CABA, Ciudad Autonoma Buenos Aires, Córdoba, Mar del Plata, Mendoza, Rosario, San Juan, San Miguel, San Miguel de Tucumán, Villa Nueva
- Életkor
- 18 év and over
- People
- 864 worldwide
- Run by
- Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00 - 3. fázisTaking peopleAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Where
- Buenos Aires, Córdoba, Rosario, San Miguel de Tucumán
- Életkor
- 5 év to 17 év
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00 - 3. fázisCsak meghívásosLong-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
- Where
- Buenos Aires, Mendoza, Quilmes, Rosario, San Miguel de Tucumán
- Életkor
- 18 év to 75 év
- People
- 680 worldwide
- Run by
- Viatris Innovation GmbH
See details and how to joinNCT06475742 · EU 2024-514354-67-00 - No phaseTaking peopleINTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
- Where
- Buenos Aires, Córdoba
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06314282 - 1. fázisTaking peopleA Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
- Where
- Buenos Aires, San Miguel de Tucumán
- Életkor
- 18 év to 70 év
- People
- 44 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00 - 1. fázisTaking peopleA Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
- Where
- Buenos Aires, Rosario, San Juan Bautista, San Miguel de Tucumán
- Életkor
- 18 év to 65 év
- People
- 142 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06576271 · EU 2024-514186-18-00 - No phaseTaking peopleArgentinian Prospective Registry of Patients With Lupus
- Where
- La Plata
- Életkor
- 18 év and over
- People
- 1500
- Run by
- Sociedad Argentina de Reumatologia
See details and how to joinNCT05470569